Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

injection of JX-594 intravenously or intratumorally two weeks prior to surgical resection. Tumors will be evaluated for evidence of JX-594 replication and pathologic response. Patients will subsequently be followed for progression-free survival and overall survival. For more information about the trial, please visit www.clinicaltrials.gov.

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 120 treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. JX-594 has had a favorable safety profile to date with predictable and generally mild side effects that typically include flu-like symptoms that resolve in 24 to 48 hours.

JX-594 is the most advanced product candidate from Jennerex's proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform.  SOLVE takes advantage of the natural attributes of poxviruses as well as their ability to be genetically engineered to produce safe, therapeutic viruses that can infect solid tumors both systemically and locally.  The vaccinia poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targe
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 /CNW/ - On Aug. 20, at its ... Canadian Medical Association (CMA) voted on and approved a ... including medicinal cannabis. Bedrocan Cannabis Corp., a leading Canadian ... CMA motion. The CMA is quite right ... with smoking any plant material, including medicinal cannabis. While ...
(Date:8/22/2014)... -- MC Medical, a subsidiary of Mitsubishi Corporation (MCM), and ... medical device company, have formally agreed to an ... system in Japan . It is anticipated ... Japan in the latter half of 2015. ... portfolio in endoscopic surgery market in Japan ...
(Date:8/22/2014)... 2014 Research and Markets has ... Particulate Respirators Industry Report 2014" report to their ... Respirators Industry Report 2014 is a professional and in-depth ... respirators industry with a focus on the Chinese situation. ... industry including definitions, classifications, applications and industry chain structure. ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... , MORRISTOWN, N.J., Dec. 14 Watson ... new program encouraging health professionals to help maintain the bone ... deprivation therapy (ADT). Nearly two million men are receiving ... effective and considered the "gold therapy," can cause bone loss ...
... , DOVER, Del., Dec. 14 Ohr Pharmaceutical ... selected Allen & Caron Inc, headquartered in Irvine, CA, ... its agency for investor relations and corporate communications. ... on developing advanced drugs for underserved therapeutic needs. The ...
Cached Medicine Technology:Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 2Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 3Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 4Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 5Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Many Americans know little ... the possibility of an outbreak in the United States, a ... they are worried that there will be a major Ebola ... they or an immediate family member will get sick with ... latest Harvard School of Public Health poll. However, those ...
(Date:8/22/2014)... Natural Clear Vision , a how-to ... own vision from legally blind to perfect 20/20 vision has ... , “There is a huge portion of the population ... and most people just think that’s the way it will ... can be pretty risky at times,” reports Michaels. “This program ...
(Date:8/22/2014)... deletion in advanced non-small cell lung cancer (NSCLC) ... in epidermal growth factor receptor (EGFR) tyrosine kinase ... BIM deletion independently predicts overall survival (OS) of ... activate the programmed cell death also known as ... been detected in 12.8% of the Asian population ...
(Date:8/22/2014)... DETROIT Rheumatoid arthritis (RA), a complex autoimmune ... adults, requires patients to not only cope with ... stressors such as disrupted work, family life and ... RA patients, residual pain and disability is common. ... to their high cost or side effects. Because ...
(Date:8/22/2014)... Advancements in ultrasound technologies make them ... to their cost-effectiveness, non-invasiveness, and absence of radiation. ... as the evolution of wireless transducers and real-time ... moving throughout 2014 and beyond. Such Ultrasound’s key ... the point-of-care (POC) testing in hospital settings, but ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3
... facts and figures has shown the dangerous increase in Type ... The number of children below five years of age, battling ... between 1985 and 2004. ,Type 1 diabetes or ... as opposed to Type 2 diabetes, which develops much later. ...
... might one day help block the spread of an illness ... ,When they fed on malaria-infected mice, the resistant ... they could eventually replace the ones that can carry the ... of the National Academy of Sciences. ,Jason Rasgon ...
... are fueling the spread of HIV in Afghanistan, the New ... there are 69-recorded cases of HIV in the country; however, ... much higher. The World Health Organization estimates that about 1,000 ... a World Bank consultant on HIV/AIDS, said the WHO estimate ...
... could result in cardio-vascular diseases, it is known. Now ... a deadlier combination. , ,At a conference ... capital of the north Indian state of Uttar Pradesh, ... condition called metabolic syndrome (MS). ,It is ...
... awareness day. This ‘celebration’ acquires specific significance in India,// ... day, 500,000 people are reported to suffer a head ... sixth most common cause of death, in the country. ... a person suffers a brain injury as a result of severe ...
... has come out strongly against the use of sunbeds or ... ,According to the Working Group on artificial UV light ... Cancer (IARC), persons who use these tanning beds in order ... themselves to higher risks of developing melanoma, the most dreaded ...
Cached Medicine News:Health News:Malaria-resistant Mosquito Developed 2Health News:Stigma, Lack of Education, Prevent the Spread of HIV in Afghanistan 2Health News:Head Injury Awareness Day 2Health News:Head Injury Awareness Day 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: